Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Autor: Tessa Prince, Derrick W. Crook, Gavin R. Screaton, A Espinosa, P Supasa, Cesar Lopez-Camacho, Juthathip Mongkolsapaya, Nicholas A. Watkins, H Thraves, Philippa C Matthews, D Georgiou, Pat Tsang, Beibei Wang, Mark A. Ainsworth, Veronica Sanchez, Malcolm G Semple, Marta S Oliveira, Wanwisa Dejnirattisai, Anne-Sophie Walker, Rutger J. Ploeg, J Milton, Tomas Surik, C Knowles, Andrew J. Pollard, Julian C. Knight, Kathryn Auckland, J K Baillie, Andrew J Kwok, Paul Klenerman, Alexander J. Mentzer, David I. Stuart, Fiona Pereira, Donal T. Skelly, Senthil Chinnakannan, H McGivern, Eleanor Barnes, John I. Bell, S Bibi, Rekha Anand, T Peto, Justine K. Rudkin, U Leuschner, C Washington, Lance Turtle, E Perez, T Berry, Monique Andersson, Sally Beer, Emily R. Adams, A Sobrinodiaz, T I de Silva, José William Martínez, D F Kelly, Chang Liu, J Whitehouse, Shona C Moore, K Jefferey, R Levin, J Slon-Campos, Julie Staves, A Hunter, H Farmer, M Fernandez Mendoza, Richard J. Cornall, Elizabeth A. Clutterbuck, Devender Roberts, David W Eyre, E. N. Smith, Sarah Hoosdally, Kate E. Dingle, Christina Dold, Miles W. Carroll
Rok vydání: 2020
Předmět:
Zdroj: Wellcome Open Research
2020, ' Antibody testing for COVID-19 : A report from the National COVID Scientific Advisory Panel ', Wellcome Open Research, vol. 5, pp. 139 . https://doi.org/10.12688/wellcomeopenres.15927.1
ISSN: 2398-502X
DOI: 10.12688/wellcomeopenres.15927.1
Popis: Background: The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices. Methods: We tested plasma for COVID (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices. We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142). Results: ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar. Conclusions: Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. However, ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.
Databáze: OpenAIRE
Externí odkaz: